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Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a seriously vexing problem, with median
survival well under 2 years and few long-term survivors. Targeted therapy has yet to produce significant advances in treatment of
these lesions in spite of advanced molecular characterization of glioblastoma and glioblastoma cancer stem cells. Recently,
immunotherapy has emerged as a promising mode for some of the hardest to treat tumors, including metastatic melanoma.
Although immunotherapy has been evaluated in glioblastoma in the past with limited success, better understanding of the fail-
ures of these therapies could lead to more successful treatments in the future. Furthermore, there is a persistent challenge for the
use of immune therapy to treat glioblastoma secondary to the existence of redundant mechanisms of tumor-mediated immune
suppression. Here we will address these mechanisms of immunosuppression in glioblastoma and therapeutic approaches.
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Regulation of the Immune System
Avariety of immune suppressive mechanisms are utilized in the
setting of glioblastoma to prevent their immune detection and
eradication (Fig. 1). For example, regulatory T cells (Tregs) can
either originate in the thymus, and are referred to as naturally
occurring Tregs (nTregs), or can be induced (iTregs) upon expo-
sure to antigens in a tolerogenic environment. Both types of
Tregs could potentially contribute to glioblastoma-mediated
immune suppression, but nTregs may predominate within the
glioblastoma microenvironment.1 Tregs suppress immune re-
sponses by secreting cytokines, such as transforming growth
factor beta (TGF-b) and interleukin (IL)-10, and by cell-to-cell
mediated contact, and in this way can prevent autoimmune
reactions.2 Cytotoxic T-lymphocyte–associated protein 4
(CTLA-4) is a surface receptor that is present on activated T
effector cells. CD28, which normally binds with B7 on an
antigen-presenting cell to provide the costimulatory signal
necessary for T cell activation, can bind this cell surface recep-
tor and induce T cell anergy.3 On Tregs, CTLA-4 can be constitu-
tively active, which contributes to their ability to suppress the
immune system.4 CTLA-4 and programmed death 1 (PD-1)
are often referred to as immune checkpoints, as these 2 help
form a system of checks and balances that keep immune prolif-
eration and activation regulated. The ligand for PD-1, pro-
grammed death ligand 1 (PD-L1), engages with PD-1 to provide
another signal to suppress activated CD4+ and CD8+ cells.5
Studies of tumor microenvironments have revealed that engage-
ment of this system is capable of inducing T cell apoptosis.6
Secreted Immunosuppressive Factors
By examining tumor cyst fluid, it was discovered that lympho-
cyte activity could be suppressed using factors secreted by
tumors.7 These secreted factors were later identified as IL-1
and TGF-b.8 –11 This discovery led to the development of trabe-
dersen, an antisense oligonucleotide that inhibited TGF-b2; but
despite initial promise, treatment by convection-enhanced
delivery ultimately did not lead to a viable treatment strat-
egy.12 Inhibitors of TGF-b receptor kinase activity are currently
in clinical testing. Although both clinical tolerability and thera-
peutic activity have been limited so far,13 preclinical studies
support their use.14 Subsequently, many other secreted factors
in the glioblastoma microenvironment have been discovered,
all of which have some varying level of effect on the immune
response to glioblastoma. For example, colony stimulating fac-
tor 1 (CSF-1), produced by gliomas,15 has been shown to polar-
ize the macrophage to a glioma-supportive M2 phenotype,
which enhances glioma progression.16 Furthermore, vascular
endothelial growth factor not only increases glioma tumorige-
nicity and growth17–20 but can also inhibit the maturation and
function of dendritic cells.21 Other cytokines include IL-10,
prostaglandin E, nitric oxide, regeneration and tolerance factor,
Received 1 June 2015; accepted 12 July 2015
# The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com.
Neuro-Oncology
Neuro-Oncology 17:vii9–vii14, 2015
doi:10.1093/neuonc/nov151
vii9
and arginase 1.22–25 Regeneration and tolerance factor was
found to inhibit the ability of natural killer (NK) cells to lyse tar-
get cells.26 Serum arginase I levels have been found to be
associated with neutrophil degranulation and immunosuppres-
sion in glioblastoma patients.27 These secreted factors may be
upregulated after gliomas undergo conventional therapy.28 Of
note, some glioma-secreted cytokines may have both immune
stimulatory and inhibitory roles depending on the context.
Granulocyte macrophage CSF, which functions as a cytokine
and growth factor for granulocytes and monocytes, can induce
myeloid-derived suppressor cells (MDSCs).29
Glioma Cell Surface Immunosuppressive
Factors
Glioma cells can express CD95 (Fas/apoptosis antigen 1) ligand
on their surface, which can induce apoptosis and thus reduce
the number of infiltrating T cells in the tumor microenviron-
ment.30,31 Similarly, CD70, by direct cell-to-cell mediated con-
tact, may have an apoptotic effect on immune cells in
vitro.32,33 Yet, the biological effects of CD70 are context depen-
dent, and immune stimulatory effects may dominate in vivo, at
least in murine glioma models.34,35 Lectin-like transcript 1 has
been shown to be a glioblastoma-expressed inhibitory ligand
for NK cells.36 The most prototypical example is, of course,
PD-L1, the ligand for PD-1, which is upregulated in the
glioblastoma microenvironment37 and may be associated
with the mesenchymal glioblastoma subtype.38 PD-L1 is ex-
pressed on immune cells and gliomas39 – 42 and has been
shown to inhibit T cell activation and induce T cell apoptosis.6,43
This upregulation in glioblastoma may be due to loss of the
tumor suppressor gene phosphatase and tensin homolog.39
Enthusiasm for immune checkpoint therapeutics is based on
the observed improvement in survival time of melanoma
patients in phase III clinical trials,44,45 which ultimately led to
FDA approval of ipilimumab. Preclinical efficacy of anti-CTLA ap-
proaches in murine models of glioma46 has provided support
for their implementation in glioblastoma patients. Several
anti–PD-1 antibodies (nivolimumab, pembrolizumab) have
also been clinically tested in melanoma patients,47 –49 with
FDA approval of nivolimumab and pembrolizumab in 2014.
The use of immune checkpoint inhibitors in glioblastoma pa-
tients has preclinical justification. For example, CTLA-4 blockade
with coadministration of IL-12 led to tumor clearance in a
murine model system, with an associated increased immune
effector response and reduction in Tregs.50 Furthermore,
anti–PD-1 blockade has been shown to improve survival in mu-
rine gliomamodel systems in combination with radiotherapy.51
Additionally, in a murine model of intracerebral glioma, combi-
natorial therapy of indoleamine 2,3-dioxygenase (IDO), CTLA-4,
and PD-L1 was curative in a marked number of mice.52 An al-
ternative/supplementary approach for inhibiting Tregs is the
use of the anti-IL2Ra antibody, daclizumab, which has been
Fig. 1. Immunosuppression in the glioblastoma microenvironment. (A) Partially driven by increased STAT3 expression, glioblastoma cells secrete
immunosuppressive factors such as TGFb-2, PGE, IL-1, IL-10 and FGL2, all of which suppress the activity of effector cells. PD-L1 expressed on its
surface also engages PD-1 to suppress effector activity. M-CSF, TGFb-1 and IL-10 skew macrophages to the immunosuppressive M2 phenotype.
(B) M2 Macrophages secrete TGFb-1 and IL-10, suppressing effector cells further. (C) Regulatory T cells secrete TGFb-1 and IL-10 as well, further
suppressing immune reactivity, while also expressing PD-L1. (C) M-CSF, TGFb-1 and IL-10, secreted by the glioblastoma, skew tumor associated
macrophages to the immunosuppressive M2 phenotype. (D) Antigen is presented to Tcells by antigen presenting cells within an MHCmolecule, but
a costimulatory signal from CD80/86 to CD28 is required for activation. CD80/86 can also suppress activity by engaging the CTLA4 receptor on the
activated T cell.
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shown to decrease Treg numbers and increase the ratio of ef-
fector T cells to Tregs in patients undergoing standard-of-care
treatment with temozolomide.53 Cumulatively, these data pro-
vide a sufficient rationale for the use of immune checkpoint in-
hibitors, and a variety of clinical trials are currently under way
using these strategies in glioblastoma patients.
Immunosuppressive Cells in the Glioma
Microenvironment
Glioblastoma patients can be profoundly immunosuppressed.
One key feature is a general paucity of CD4-positive T cells in
peripheral blood with an increased proportion of Tregs.54 Che-
mokine C-C ligand 2, produced by glioblastoma cells, and other
soluble factors55 can trigger the trafficking of Tregs to the tumor
microenvironment.56 However, not all glioblastomas show a sig-
nificant infiltration of Tregs,57 suggesting a heterogeneity of im-
mune suppressive mechanisms. The functional activity of the
Tregs in the tumor microenvironment may be further enhanced
by the activity of IDO, an intracellular enzyme overexpressed in
many cancers, including gliomas, which suppresses T cell activa-
tion and proliferation by creating a tryptophan shortage.58
Microglia and macrophages, the latter derived from mono-
cytes, can constitute up to 12% of the tumor mass within gli-
omas.59 Macrophages are believed to be activated either by the
classical pathway, involving bacterial products and interferon-g
(ie, M1), or by alternative activation with T-helper 2–type cyto-
kines such as IL-4, IL-10, IL-13, and/or macrophage CSF.60 The
M2 macrophages generally express CD163 and CD204 and dis-
play an immune suppressive phenotype. Glioblastomas have
the highest frequency of infiltration by tumor-associated mac-
rophages, which tend to be of the M2 lineage.61 Factors pro-
duced by glioblastoma cancer stem cells may be responsible
for the skew to the M2 phenotype in the glioblastoma microen-
vironment.62 In a study of an immune modulating microRNA,
miR-142-3p, it was discovered that M2 macrophages are
dependent on the stimulation of the TGF-b receptor pathway,
unlike M1 macrophages.63 Moreover, tumor-associated macro-
phages have been shown to enhance the invasiveness of glio-
ma stem cells (GSCs) via the TGF-b1 signaling pathway.64
MDSCs also contribute to glioblastoma-mediated immune sup-
pression.65,66 Normal monocytes exposed to glioma cells
acquire properties akin to those of MDSCs.67 Both galectin-1
and arginase have been tied to MDSC suppressor function.68
Whereas both CD14-positive and CD15-positive MDSC subtypes
have been found in the blood of glioma patients, it is the CD15
subtype that was found to be upregulated in the glioblastoma
microenvironment.69 Based on data from other types of malig-
nancies,70 it is likely that NK cells also play a key role in
glioblastoma-mediated immune suppression, and this is an
area of active investigation. An emerging area of therapeutic
development has been directed toward targeting innate
immunity.16
Hubs of Tumor-Mediated
Immunosuppression
Given the heterogeneity and redundancy of immune suppres-
sive mechanisms in glioblastoma, identifying key hubs that
mediate many of these functions is theoretically appealing.
Signal transducer and activator of transcription 3 (STAT3) is a
transcription factor that has been found to be ubiquitously
expressed in glioblastoma cells.71 IL-10 activation of STAT3 in
macrophages inhibits their proliferation.72 Blocking STAT3 acti-
vation in the glioma microenvironment leads to an upregula-
tion of immune-stimulatory cytokines IL-2, IL-4, IL-12, and
IL-15 and of costimulatory molecules CD80 and CD86.72 GSCs
are known to be resistant to conventional treatment methods
and are likely to be capable of restoring all of the cells within a
glioblastoma after other portions of the tumor are effectively
treated.73 GSCs also cause immunosuppression in the glioma
microenvironment by activating the STAT3 pathway and by in-
creasing the number of Tregs.74 Hypoxia further induces STAT3
and its transcriptionally regulated downstream pathways,
those of hypoxia inducible factor 1 a and vascular endothelial
growth factor.75 A variety of approaches targeting STAT3 are
currently in preclinical development.75–86
A second hub of glioblastoma-mediated immune suppres-
sion has recently been described. Fibrinogen-like protein 2
(FGL2) is a secreted factor that has been implicated by many
different investigators as immunosuppressive. A recent study
has shown that FGL2 is overexpressed in glioblastoma rela-
tive to low-grade glioma samples.87 An examination of data
from The Cancer Genome Atlas showed that high levels of
FGL2 mRNA portended worse survival for patients than did
low expression. Furthermore, higher protein levels of FGL2
were found in high-grade gliomas than in low-grade tumors.
FGL2 augmented glioma immunosuppression by increasing
the expression levels of PD-1, expanding the frequency of
tumor-supportive M2 macrophages, and enhancing the num-
ber of MDSCs and Tregs, especially within the glioma microen-
vironment. Anti-FGL2 antibody treatment not only increased
survival time in a murine model of intracerebral gliomas but
also reduced the number of Tregs, M2 immunosuppressive mac-
rophages, and MDSCs, and decreased the expression of PD-1.
Given these data, FGL2 may be an important immunosup-
pressive factor that merits further targeting, specifically in
glioblastoma.
Placing Immune Suppressive Targeting into
Therapeutic Context
Although there is currently great enthusiasm for the use of
modulators to inhibit immune suppression, one needs to bear
in mind that multiple steps are necessary for the development
of an optimal antitumor immune response. First, there must be
an immunological target (ie, antigen) present for the immune
system to be directed toward. Examples of glioblastoma-
specific targets and approaches include: epidermal growth fac-
tor receptor variant III, isocitrate dehydrogenase 1 mutation,
and the IMA-950 glioblastoma profile panel. In the setting of
minimal antigen or target expression, alternative immunother-
apeutic approaches such as NK chimeric antigen receptor im-
munotherapy could be utilized. Second, the immune system
must be activated. There are a variety of ways to do this, includ-
ing triggering/engaging a costimulatory molecule such as
4-1BB or OX40; providing proinflammatory cytokines such as
granulocyte macrophage CSF, interferon-g, IL-12, and IL-15;
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engaging innate immunity with toll-like receptor agonists such
as cytosine-phosphate-guanine or poly–inosinic:cytidylic acid;
providing activated antigen-presenting cells by adoptive trans-
fer of dendritic cells; or using stimulator of interferon gene
(“Sting”) agonists. Thereafter, there needs to be sufficient traf-
ficking and infiltration into the tumor site. This may depend on
tumor expression of chemokines such as CX3CR1. Finally, there
must be maintenance of the immune effector function that is
blocked and inhibited by tumor-mediated immune suppres-
sion. Strategies that can be employed for this function include,
but are not limited to, inhibition of immunosuppression cyto-
kines such as TGF-b and IL-10; targeting of key hubs of multi-
modality immune suppression such as STAT3 and FGL2; and,
the most successful thus far, use of immune checkpoint
inhibitors.
As we move into the next generation of immunotherapeutic
strategies, it is evident that combinatorial approaches that ad-
dress each step in this continuum will be necessary to maxi-
mally impact outcomes. One needs to bear in mind that
there is a great deal of plasticity within glioblastoma, and mul-
tiple operational mechanisms of immune suppression exist.
When one mechanism of immune suppression is inhibited,
other mechanisms can assume a dominant role. Thus, there
has been an increasing interest in directing therapeutics to tar-
gets that control multiple mechanisms of tumor-mediated im-
mune suppression. Until optimal combinatorial approaches are
implemented, it is likely that glioblastoma patients will be strat-
ified and selected for various immune therapeutic strategies
based on immune biomarkers, similar to the strategies based
on genomic profiling for targeted therapeutics.
Funding
The Dr. Marnie Rose Foundation and the National Institutes of Health
CA1208113, P50 CA127001 and P30 CA016672 (A.B.H.).
Conflict of interest statement. M.W. has received research grants from
Acceleron, Actelion, Alpinia Institute, Bayer, Isarna, MSD, Merck & Co,
Novocure, PIQUR, and Roche and honoraria for lectures, advisory
board participation, or consulting from Celldex, Immunocellular, Isarna,
Magforce, MSD, Merck & Co, Northwest Biotherapeutics, Novocure,
Pfizer, Roche and Teva. A.B.H. has received research grants from
Merck, has been a paid consultant for Bristol Myers Squibb, serves on
the Scientific Advisory Board of Caris Life Sciences, holds equity in
Caris Life Sciences, and receives licensing and royalty fees from Celldex
Therapeutics. E.N. has no conflicts of interest to report.
References
1. Wainwright DA, Sengupta S, Han Y, et al. Thymus-derived rather
than tumor-induced regulatory T cells predominate in brain
tumors. Neuro Oncol. 2011;13(12):1308–1323.
2. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances
on self tolerance and autoimmunity. Nature immunology. 2010;
11(1):7–13.
3. Thompson CB, Allison JP. The emerging role of CTLA-4 as an
immune attenuator. Immun. 1997;7(4):445–450.
4. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic
self-tolerance maintained by CD25(+)CD4(+) regulatory T cells
constitutively expressing cytotoxic T lymphocyte-associated
antigen 4. J Exp Med. 2000;192(2):303–310.
5. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the
B7-related molecule B7-H1 by glioma cells: a potential
mechanism of immune paralysis. Cancer Res. 2003;63(21):
7462–7467.
6. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1
promotes T-cell apoptosis: a potential mechanism of immune
evasion. Nat Med. 2002;8(8):793–800.
7. Kikuchi K, Neuwelt EA. Presence of immunosuppressive factors in
brain-tumor cyst fluid. J Neurosurg. 1983;59(5):790–799.
8. de Martin R, Haendler B, Hofer-Warbinek R, et al. Complementary
DNA for human glioblastoma-derived T cell suppressor factor, a
novel member of the transforming growth factor-beta gene
family. EMBO J. 1987;6(12):3673–3677.
9. Fontana A, Hengartner H, de Tribolet N, et al. Glioblastoma cells
release interleukin 1 and factors inhibiting interleukin
2-mediated effects. J Immunol. 1984;132(4):1837–1844.
10. Wrann M, Bodmer S, de Martin R, et al. T cell suppressor factor
from human glioblastoma cells is a 12.5-kd protein closely
related to transforming growth factor-beta. EMBO J. 1987;6(6):
1633–1636.
11. Frei K, Gramatzki D, Tritschler I, et al. Transforming growth
factor-beta pathway activity in glioblastoma. Oncotarget. 2015;
6(8):5963–5977.
12. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for
high-grade glioma with the TGF-beta2 inhibitor trabedersen:
results of a randomized and controlled phase IIb study. Neuro
Oncol. 2011;13(1):132–142.
13. Rodon J, Carducci MA, Sepulveda-Sanchez JM, et al.
First-in-human dose study of the novel transforming growth
factor-beta receptor I kinase inhibitor LY2157299 monohydrate
in patients with advanced cancer and glioma. Clin Cancer Res.
2015;21(3):553–560.
14. Ueda R, Fujita M, Zhu X, et al. Systemic inhibition of transforming
growth factor-beta in glioma-bearing mice improves the
therapeutic efficacy of glioma-associated antigen peptide
vaccines. Clin Cancer Res. 2009;15(21):6551–6559.
15. Alterman RL, Stanley ER. Colony stimulating factor-1 expression in
human glioma. Mol Chem Neuropathol. 1994;21(2–3):177–188.
16. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition
alters macrophage polarization and blocks glioma progression.
Nat Med. 2013;19(10):1264–1272.
17. Deryugina EI, Soroceanu L, Strongin AY. Up-regulation of vascular
endothelial growth factor by membrane-type 1 matrix
metalloproteinase stimulates human glioma xenograft growth
and angiogenesis. Cancer Res. 2002;62(2):580–588.
18. Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor
stimulates vascular endothelial growth factor production by
human malignant glioma cells: a model of glioblastoma
multiforme pathophysiology. Mol Biol Cell. 1993;4(1):121–133.
19. Ke LD, Shi YX, Yung WK. VEGF(121), VEGF(165) overexpression
enhances tumorigenicity in U251 MG but not in NG-1 glioma
cells. Cancer Res. 2002;62(6):1854–1861.
20. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth
factor induced by hypoxia may mediate hypoxia-initiated
angiogenesis. Nature. 1992;359(6398):843–845.
21. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular
endothelial growth factor by human tumors inhibits the
Nduom et al.: Immunosuppression and CNS tumors
vii12
functional maturation of dendritic cells. Nat Med. 1996;2(10):
1096–1103. [Erratum appears in Nat Med 1996 Nov;2(11):1267]
22. Hishii M, Nitta T, Ishida H, et al. Human glioma-derived
interleukin-10 inhibits antitumor immune responses in vitro.
Neurosurg. 1995;37(6):1160–1166; discussion 1166–1167.
23. Nitta T, Hishii M, Sato K, Okumura K. Selective expression of
interleukin-10 gene within glioblastoma multiforme. Brain Res.
1994;649(1-2):122–128.
24. Kuppner MC, Sawamura Y, Hamou MF, et al. Influence of PGE2-
and cAMP-modulating agents on human glioblastoma cell killing
by interleukin-2-activated lymphocytes. J Neurosurg. 1990;72(4):
619–625.
25. Hegardt P, Widegren B, Sjo¨gren HO. Nitric-oxide–dependent
systemic immunosuppression in animals with progressively
growingmalignant gliomas. Cell Immunol. 2000;200(2):116–127.
26. Roth P, Aulwurm S, Gekel I, et al. Regeneration and tolerance factor:
a novel mediator of glioblastoma-associated immunosuppression.
Cancer Res. 2006;66(7):3852–3858.
27. Sippel TR, White J, Nag K, et al. Neutrophil degranulation and
immunosuppression in patients with GBM: restoration of cellular
immune function by targeting arginase I. Clin Cancer Res. 2011;
17(22):6992–7002.
28. Authier A, Farrand KJ, Broadley KW, et al. Enhanced
immunosuppression by therapy-exposed glioblastoma multiforme
tumor cells. Int J Cancer. 2015;136(11):2566–2578.
29. Kohanbash G, McKaveney K, Sakaki M, et al. GM-CSF promotes the
immunosuppressive activity of glioma-infiltrating myeloid cells
through interleukin-4 receptor-alpha. Cancer Res. 2013;73(21):
6413–6423.
30. Badie B, Schartner J, Prabakaran S, et al. Expression of Fas ligand
by microglia: possible role in glioma immune evasion. J
Neuroimmunol. 2001;120(1-2):19–24.
31. Weller M, Weinstock C, Will C, et al. CD95-dependent T cell killing
by glioma cells expressing CD95 ligand: more on tumor immune
escape, the CD95 counterattack, and the immune privilege of
the brain. Cell Physiol Biochem. 1997;7:282–288.
32. Wischhusen J, Jung G, Radovanovic I, et al. Identification of
CD70-mediated apoptosis of immune effector cells as a novel
immune escape pathway of human glioblastoma. Cancer Res.
2002;62(9):2592–2599.
33. Chahlavi A, Rayman P, Richmond AL, et al. Glioblastomas induce
T-lymphocyte death by two distinct pathways involving
gangliosides and CD70. Cancer Res. 2005;65(12):5428–5438.
34. Aulwurm S, Wischhusen J, Friese M, et al. Immune stimulatory
effects of CD70 override CD70-mediated immune cell apoptosis
in rodent glioma models and confer long-lasting antiglioma
immunity in vivo. Int J Cancer. 2006;118(7):1728–1735.
35. Miller J, Eisele G, Tabatabai G, et al. Soluble CD70: a novel
immunotherapeutic agent for experimental glioblastoma. J
Neurosurg. 2010;113(2):280–285.
36. Roth P, Mittelbronn M, Wick W, et al. Malignant glioma cells
counteract antitumor immune responses through expression of
lectin-like transcript-1. Cancer Res. 2007;67(8):3540–3544.
37. Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand
1 expression and tumor-infiltrating lymphocytes in glioblastoma.
Neuro Oncol. 2015;17(8):1064–1075.
38. Doucette TA, Rao G, Rao A, et al. Immune heterogeneity of
glioblastoma subtypes: extrapolation from The Cancer Genome
Atlas. Cancer Immunol Res. 2013;1(2):112–122.
39. Parsa AT,Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN
function increases B7-H1 expression and immunoresistance in
glioma. Nat Med. 2007;13(1):84–88.
40. Avril T, Saikali S, Vauleon E, et al. Distinct effects of human
glioblastoma immunoregulatory molecules programmed cell
death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO)
on tumour-specific T cell functions. J Neuroimmunol. 2010;
225(1–2):22–33.
41. Bloch O, Crane CA, Kaur R, et al. Gliomas promote
immunosuppression through induction of B7-H1 expression in
tumor-associated macrophages. Clin Cancer Res. 2013;19(12):
3165–3175.
42. Liu Y, Carlsson R, Ambjorn M, et al. PD-L1 Expression by neurons
nearby tumors indicates better prognosis in glioblastoma
patients. J Neurosci. 2013;33(35):14231–14245.
43. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand
1 interacts specifically with the B7-1 costimulatory molecule to
inhibit T cell responses. Immunity. 2007;27(1):111–122.
44. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival
with ipilimumab in patients with metastatic melanoma. N Engl J
Med. 2010;363(8):711–723.
45. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus
dacarbazine for previously untreated metastatic melanoma.
N Engl J Med. 2011;364(26):2517–2526.
46. Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade
ameliorates glioma-induced changes to the CD4+ T cell
compartment without affecting regulatory T-cell function. Clin
Cancer Res. 2007;13(7):2158–2167.
47. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with
lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;
369(2):134–144.
48. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor
remission, and long-term safety in patients with advanced
melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):
1020–1030.
49. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-
receptor-1 treatment with pembrolizumab in ipilimumab-
refractory advanced melanoma: a randomised dose-comparison
cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–1117.
50. Vom Berg J, Vrohlings M, Haller S, et al. Intratumoral IL-12
combined with CTLA-4 blockade elicits T cell-mediated glioma
rejection. J Exp Med. 2013;210(13):2803–2811.
51. Zeng J, See AP, Phallen J, et al. Anti–PD-1 blockade and
stereotactic radiation produce long-term survival in mice with
intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):
343–349.
52. Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic
efficacy utilizing combinatorial blockade against IDO, CTLA-4
and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;
20(20):5290–5301.
53. Sampson JH, Schmittling RJ, Archer GE, et al. A pilot study of
IL-2Ralpha blockade during lymphopenia depletes regulatory
T-cells and correlates with enhanced immunity in patients with
glioblastoma. PLoS One. 2012;7(2):e31046.
54. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory
T-cell fraction amidst a diminished CD4 compartment explains
cellular immune defects in patients with malignant glioma.
Cancer Res. 2006;66(6):3294–3302.
55. Crane CA, Ahn BJ, Han SJ, et al. Soluble factors secreted by
glioblastoma cell lines facilitate recruitment, survival, and
Nduom et al.: Immunosuppression and CNS tumors
Neuro-Oncology vii13
expansion of regulatory T cells: implications for immunotherapy.
Neuro Oncol. 2012;14(5):584–595.
56. Jordan JT, Sun W, Hussain SF, et al. Preferential migration of
regulatory T cells mediated by glioma-secreted chemokines can
be blocked with chemotherapy. Cancer Immunol Immunother.
2008;57(1):123–131.
57. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and
prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Clin Cancer Res. 2008;14(16):5166–5172.
58. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral
immune resistance mechanism based on tryptophan
degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;
9(10):1269–1274.
59. Badie B, Schartner JM. Flow cytometric characterization of
tumor-associated macrophages in experimental gliomas.
Neurosurg. 2000;46(4):957–961; discussion 961–962.
60. Gordon S. Alternative activation of macrophages. Nat Rev
Immunol. 2003;3(1):23–35.
61. Komohara Y, Ohnishi K, Kuratsu J, et al. Possible involvement of
the M2 anti-inflammatory macrophage phenotype in growth of
human gliomas. J Pathol. 2008;216(1):15–24.
62. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce
immunosuppressive macrophages/microglia. Neuro Oncol. 2010;
12(11):1113–1125.
63. Xu S, Wei J, Wang F, et al. Effect of miR-142–3p on the M2
macrophage and therapeutic efficacy against murine glioblastoma.
J Natl Cancer Inst. 2014;106(8); doi: 10.1093/jnci/dju162.
64. Ye XZ, Xu SL, Xin YH, et al. Tumor-associated microglia/
macrophages enhance the invasion of glioma stem-like cells via
TGF-beta1 signaling pathway. J Immunol. 2012;189(1):444–453.
65. Almand B, Clark JI, Nikitina E, et al. Increased production of
immature myeloid cells in cancer patients: a mechanism of
immunosuppression in cancer. J Immunol. 2001;166(1):
678–689.
66. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of
myeloid-derived suppressor cells in tumor-bearing mice. J
Immunol. 2008;181(8):5791–5802.
67. Rodrigues JC, Gonzalez GC, Zhang L, et al. Normal human
monocytes exposed to glioma cells acquire myeloid-derived
suppressor cell-like properties. Neuro Oncol. 2010;12(4):351–365.
68. Verschuere T, Toelen J, Maes W, et al. Glioma-derived galectin-1
regulates innate and adaptive antitumor immunity. Int J Cancer.
2014;134(4):873–884.
69. Gielen PR, Schulte BM, Kers-Rebel ED, et al. Increase in both
CD14-positive and CD15-positive myeloid-derived suppressor cell
subpopulations in the blood of patients with glioma but
predominance of CD15-positive myeloid-derived suppressor cells
in glioma tissue. J Neuropathol Exp Neurol. 2015;74(5):390–400.
70. O’Sullivan T, Saddawi-Konefka R, Vermi W, et al. Cancer
immunoediting by the innate immune system in the absence of
adaptive immunity. J Exp Med. 2012;209(10):1869–1882.
71. Abou-Ghazal M, Yang DS, Qiao W, et al. The incidence, correlation
with tumor-infiltrating inflammation, and prognosis of
phosphorylated STAT3 expression in human gliomas. Clin Cancer
Res. 2008;14(24):8228–8235.
72. O’Farrell AM, Liu Y, Moore KW, et al. IL-10 inhibits macrophage
activation and proliferation by distinct signaling mechanisms:
evidence for Stat3-dependent and -independent pathways.
EMBO J. 1998;17(4):1006–1018.
73. Nduom EK, Hadjipanayis CG, Van Meir EG. Glioblastoma cancer
stem-like cells: implications for pathogenesis and treatment.
Cancer J. 2012;18(1):100–106.
74. Wei J, Barr J, Kong LY, et al. Glioblastoma cancer-initiating cells
inhibit T-cell proliferation and effector responses by the signal
transducers and activators of transcription 3 pathway. Mol
Cancer Ther. 2010;9(1):67–78.
75. Wei J, Wu A, Kong LY, et al. Hypoxia potentiates glioma-mediated
immunosuppression. PLoS One. 2011;6(1):e16195.
76. Hussain SF, Kong LY, Jordan J, et al. A novel small molecule
inhibitor of signal transducers and activators of transcription
3 reverses immune tolerance in malignant glioma patients.
Cancer Res. 2007;67(20):9630–9636.
77. Ball S, Li C, Li PK, et al. The small molecule, LLL12, inhibits STAT3
phosphorylation and induces apoptosis in medulloblastoma and
glioblastoma cells. PloS One. 2011;6(4):e18820.
78. Sai K, Wang S, Balasubramaniyan V, et al. Induction of cell-cycle
arrest and apoptosis in glioblastoma stem-like cells by WP1193,
a novel small molecule inhibitor of the JAK2/STAT3 pathway.
J Neurooncol. 2012;107(3):487–501.
79. Kohsaka S, Wang L, Yachi K, et al. STAT3 inhibition overcomes
temozolomide resistance in glioblastoma by downregulating
MGMT expression. Mol Cancer Ther. 2012;11(6):1289–1299.
80. de Groot J, Liang J, Kong LY, et al. Modulating antiangiogenic
resistance by inhibiting the signal transducer and activator of
transcription 3 pathway in glioblastoma. Oncotarget. 2012;3(9):
1036–1048.
81. McFarland BC, Gray GK, Nozell SE, et al. Activation of the
NF-kappaB pathway by the STAT3 inhibitor JSI-124 in human
glioblastoma cells. Mol Cancer Res. 2013;11(5):494–505.
82. Wei J, Wang F, Kong LY, et al. MiR-124 inhibits STAT3 signaling to
enhance T cell–mediated immune clearance of glioma. Cancer
Res. 2013;73(13):3913–3926.
83. Ashizawa T, Akiyama Y, Miyata H, et al. Effect of the STAT3 inhibitor
STX-0119 on the proliferation of a temozolomide-resistant
glioblastoma cell line. Int J Oncol. 2014;45(1):411–418.
84. Zheng Q, Han L, Dong Y, et al. JAK2/STAT3 targeted therapy
suppresses tumor invasion via disruption of the EGFRvIII/JAK2/
STAT3 axis and associated focal adhesion in EGFRvIII-expressing
glioblastoma. Neuro Oncol. 2014;16(9):1229–1243.
85. Liang Q, Ma C, Zhao Y, et al. Inhibition of STAT3 reduces
astrocytoma cell invasion and constitutive activation of STAT3
predicts poor prognosis in human astrocytoma. PloS One. 2013;
8(12):e84723.
86. Fujita M, Zhu X, Sasaki K, et al. Inhibition of STAT3 promotes the
efficacy of adoptive transfer therapy using type-1 CTLs by
modulation of the immunological microenvironment in a
murine intracranial glioma. J Immunol. 2008;180(4):2089–2098.
87. Yan J, Kong LY, Hu J, et al. FGL2 as a multimodality regulator
of tumor-mediated immune suppression and therapeutic target
in gliomas. J Natl Cancer Inst. 2015;107(8); doi: 10.1371/
journal.pone.0018820.
Nduom et al.: Immunosuppression and CNS tumors
vii14
